Drugs / BBT-176
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04820023 | Apr 2021 → Nov 2023 | non-small cell lung carcinoma | Bridge Biotherapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBT-176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04820023 ↗ |
| Action | Inhibit | “BBT-176 is a fourth-generation EGFR inhibitor showing promising preclinical activity against NSCLC resistant to current EGFR TKI, with early clinical efficacy and safety.” PMID 37249619 ↗ Aug 2023 |
| Route | Oral | “BBT-176 given orally alone, QD” NCT04820023 ↗ |
| Target | EGFR | “We have developed a new EGFR tyrosine kinase inhibitor (TKI), BBT-176, targeting the C797S mutation.” PMID 37249619 ↗ Aug 2023 |